Key concepts in biosimilar medicines: What physicians must know

Iskit A. B.

NORTHERN CLINICS OF ISTANBUL, vol.9, no.1, pp.86-91, 2022 (ESCI) identifier identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 9 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.14744/nci.2021.84669
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.86-91
  • Keywords: Biologic drugs, biosimilar, biotechnology
  • Hacettepe University Affiliated: Yes


Biologics' are a class of medications produced by living cells using recombinant DNA technology. Biologics have had an important impact in many areas of medicine, and in particular in rheumatology and oncology. However, the high cost of these agents is a growing concern, particularly as more products become available and their use for the treatment of immunemediated inflammatory diseases continues to expand. Biosimilars, also called follow-on biologics, have been viewed as a potential cost-saving alternative to traditional therapies. Currently, a product can be considered biosimilar to a reference product if there are no clinically meaningful differences in terms of safety, purity, and potency. In this review, the most important key concepts about biosimilars were summarized for physicians emphasizing the status in Turkey